A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.
about
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyAndrogen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazolePharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadismGonadotropins regulate rat testicular tight junctions in vivo.Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiencySuppression of spermatogenesis before grafting increases survival and supports resurgence of spermatogenesis in adult mouse testis.An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men.Acute testosterone deprivation reduces insulin sensitivity in menAcute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in menSerum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial.Male contraception: past, present and future.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamicsNew considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Effects of GnRH antagonists vs agonists in domestic carnivores, a review.Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men.Impact of acute biochemical castration on insulin sensitivity in healthy adult men.Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.Dose-response effects of sex hormone concentrations on body composition and adipokines in medically castrated healthy men administered graded doses of testosterone gel.Advances in male contraceptionAdvances in male hormonal contraception
P2860
Q28829239-292C1E77-AF45-47EF-BD65-8A9DA8B86FD4Q30537242-9D440A33-ADAC-427F-A628-332EA46D6A39Q33667466-1EA5A5C2-AC92-491F-AFA9-E10B0B952BCFQ33874433-AE12B849-DF82-4B20-9204-4CD10D742EF7Q34032007-FF0DBE18-3DB2-4D2D-83FB-3ADD5ADEAC52Q34034793-38AE9236-945B-46E8-AE12-F150186309FFQ34214898-61962756-DD14-4ACD-BA36-4E278FCA466FQ34618368-9086FA10-FDCB-43F7-B5B4-5CE9252EAFE4Q34722629-3E9EADF2-2449-42CE-9787-741CD92AC3E0Q34758520-9080D5D8-50A9-44AC-9C34-B9B65C58E8AAQ35573457-5FA33B43-99FD-4DD0-885D-D6E79CE26FE6Q35831025-1078A32E-231D-4DC7-B7D4-3C99B3DDE6FEQ36501771-CB820100-27BB-4524-9FCB-DB5CA2905D59Q36665752-62175AAC-EA6C-43D6-8A68-E72FD267DB96Q36876855-474A3F49-FA3A-411B-A696-98579E3723EFQ37291951-F5973C67-1514-4125-A115-5133EE883BBCQ38023124-58B39BBC-CF1F-40FD-9ADE-C4795F35BDACQ38070901-AE88F259-1B5E-4BE3-89EF-BB81A69BC2C3Q41646633-C0E931FB-6DDF-4B66-B7F6-F11F79E71D0EQ43090563-B955FD07-7B2A-48CE-8432-113F3CE85A99Q46849827-6D27BCA2-A4C3-4A08-926D-5537AAB4264AQ48043043-43740290-7AD5-4D9B-8866-98B931E15A14Q56679619-E0867453-D57C-496C-AC40-74EF249C073DQ56998406-CCEE46AC-CECC-4478-A56D-B92FEC79F7EB
P2860
A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A single dose of the potent go ...... 2 weeks in healthy young men.
@en
A single dose of the potent go ...... 2 weeks in healthy young men.
@nl
type
label
A single dose of the potent go ...... 2 weeks in healthy young men.
@en
A single dose of the potent go ...... 2 weeks in healthy young men.
@nl
prefLabel
A single dose of the potent go ...... 2 weeks in healthy young men.
@en
A single dose of the potent go ...... 2 weeks in healthy young men.
@nl
P2093
P356
P1476
A single dose of the potent go ...... 2 weeks in healthy young men.
@en
P2093
Bradley D Anawalt
John K Amory
Stephanie Page
William J Bremner
P304
P356
10.1210/JC.2003-032123
P407
P577
2004-12-01T00:00:00Z